Producing method of mesenchymal stem cell for prevention or treatment of brain neuronal disease including ghrelin treatment and use thereof
Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.
1. A method for producing mesenchymal stem cells for treating brain neuronal diseases, the method comprising treating mesenchymal stem cells with ghrelin at a concentration of 1 nM to 100 nM for 6 to 12 hours, wherein the treatment results in the mesenchymal stem cells having an increased AgRP (Agouti related peptide) expression level compared to mesenchymal stem cells not treated with ghrelin, wherein said mesenchymal stem cells are derived by Wharton's jelly.
2. The method of claim 1 , wherein the brain neuronal disease is selected from a group consisting of Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, Lou Gehrig disease, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory metabolic disorder, brain dysfunction and dementia.